Design Therapeutics (DSGN) Operating Leases (2021 - 2026)
Design Therapeutics (DSGN) posted quarterly Operating Leases of $2.0 million for Q2 2026, up 84.3% year-over-year from $1.1 million in Q2 2025, and down 7.6% on a QoQ basis from $2.2 million in Q1 2026.
Design Therapeutics (DSGN) Operating Leases (2021 - 2026) Analysis & Trends
Design Therapeutics has reported Operating Leases for 6 years, with the latest figure at $2.0 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $2.0 million, up 84.3% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.0 million (up 84.3% YoY), and the FY2025 annual result was $645000.0, down 57.95% from the prior year.
- Operating Leases fell to $2.0 million in Q2 2026, from $2.2 million in the prior quarter.
- Over five years, Operating Leases peaked at $3.4 million in Q2 2022 and troughed at $645000.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $2.2 million in 2024 frame the typical range for Operating Leases.
- The widest annual swing landed in 2025, when Operating Leases slumped 57.95%; it then surged 84.3% in 2026.
- A 5-year view of Operating Leases shows it stood at $3.1 million in 2022, then decreased by 23.5% to $2.3 million in 2023, then plunged by 34.28% to $1.5 million in 2024, then slumped by 57.95% to $645000.0 in 2025, then jumped by 214.88% to $2.0 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $2.0 million in Q2 2026, $2.2 million in Q1 2026, and $645000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 645,000.00 |
| Sep 30, 2025 | 877,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.52 Mn |
| Jun 30, 2023 | 2.70 Mn |
| Mar 31, 2023 | 2.88 Mn |
| Dec 31, 2022 | 3.05 Mn |
| Sep 30, 2022 | 3.22 Mn |
| Jun 30, 2022 | 3.38 Mn |
| Mar 31, 2022 | 3.01 Mn |
| Dec 31, 2021 | 3.14 Mn |
| Sep 30, 2021 | 3.27 Mn |